Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 6:30PM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), announced today that the
Company will present at the 42nd Annual J.P. Morgan Healthcare
Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
The presentation will be webcast and an archived recording will
be available for replay in the Investors section of the Madrigal
website after the event.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
liver-directed THR-β agonist oral therapy that is designed to
target key underlying causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
